Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the
treatment of subjects with untreated angioimmunoblastic T cell lymphoma.